Evotec: vision of a one-stop-partner 'closer than ever before'

By Melissa Fassbender contact

- Last updated on GMT

Evotec announced that it had entered into a definitive agreement to acquire Aptuit on July 30, 2017. (Image: iStock/Pogonici)
Evotec announced that it had entered into a definitive agreement to acquire Aptuit on July 30, 2017. (Image: iStock/Pogonici)

Related tags: Economics

Evotec AG has acquired Aptuit for $300m as CRO consolidation continues – bringing innovative products forward faster and at a lower cost, says CEO.

Dr. Werner Lanthaler, CEO of Evotec told Outsourcing-Pharma.com the company wants to offer “an even better and more complete translational process from the discovery stage to the clinical manufacturing for its partners​.”

The vision of a one-stop-partner for innovation is closer than ever before​,” he added.

Following the completed transaction, Evotec will have offices​ in the US, UK, France, Italy, Switzerland, and Germany, with approximately 2,000 employees, nearly 750 of whom will be joining from Aptuit.

As for how the companies will be integrated, Lanthaler explained the global centers of excellence will stay as they are – “In Oxford the two companies are next door to each other​,” he explained.

The cultures are very similar so we expect a smooth integration​,” he added. “The market presence and offering for the services will stay as it is​.”

The transaction is expected to close in the third quarter of 2017.

CRO consolidation

In response to continued industry consolidation, Lanthaler commented that external innovation is good for all industry players, “as it brings highly innovative products forward at higher speed and lower cost​,” he said. “So this should just be the start of a long term megatrend of how the value chain is re-organized​.”

The acquisition follows in a series of M&A activity, including Evotec's purchase of Cyprotex in December 2016. As Outsourcing-Pharma.com reported​ at the time, the preclinical CRO specializes in ADME-Tox and DMPK.

Aptuit has also made several acquisitions, joining Evotec after purchasing Exquiron and Kuecept in 2016.

The addition of Swiss CRO Exquiron Biotech​ enhanced Aptuit’s drug identification and validation services. Kuecept’s acquisition​ helped meet a demand for specialist drug pre-formulation, formulation prototyping, and formulation development services.

Related news

Related products

show more


Lyophilization Scale-Up and Tech Transfer

Baxter BioPharma Solutions | 12-Mar-2018 | Technical / White Paper

There are few challenges when increasing the scale of production for a solution formulation, but the challenges drastically increase when the formulation...

Leveraging Best Practices in Primary Packaging

Leveraging Best Practices in Primary Packaging

Catalent Pharma Solutions | 05-Mar-2018 | Technical / White Paper

When planning a clinical trial, overlooking the importance of primary packaging can be a mistake. From stability concerns to labeling to patient compliance...

VDS groß

Meet the challenges of complex injectables

Vetter Pharma International GmbH | 07-Nov-2017 | Technical / White Paper

In the time it takes from the exciting discovery phase to the rigorous demands of a commercial launch, unexpected scientific and technical challenges can...


Process Development for Lyophilized Products

Baxter BioPharma Solutions | 30-Oct-2017 | Application Note

Baxter approaches formulation and process development with the intention of identifying the failure points for the product. Knowing where the product fails...

Related suppliers